Drugs / CD19/BCMA Lupus Nephritis Targeted CAR T-cells
CD19/BCMA Lupus Nephritis Targeted CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06785519 | Jan 2025 → Oct 2027 expected | lupus nephritis | He Huang | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/BCMA Lupus Nephritis Targeted CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06785519 ↗ |
| Modality | Cell therapy | “CD19/BCMA Lupus Nephritis Targeted CAR T-cells” NCT06785519 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT06785519 ↗ |